// App-Quantinova.ai

2550 : Phase I study of BPM 31510 in advanced solid tumors: Omics-based molecular correlation to outcome for patient stratification.

Researchers

Presenter

  • Manish A. Shah

Principal Investigators

  • Vivek Subbiah

  • Niven R. Narain

  • Rangaprasad Sarangarajan

  • Michael Kiebish

  • Vivek Vishnudas

  • Eric M Grund

  • Yezhou Sun

  • Gregory M Miller

  • Leonardo O Rodrigues

  • Viacheslav R Akmaev

  • Susan Brouwer

  • Janice Stevens

  • Ralph Zinner

  • Peter Paul Yu

Medical Centers

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Berg LLC, Framingham, MA

  • Berg LLC, Framingham, MA

  • Berg LLC, Framingham, MA

  • Palo Alto Medical Foundation, Mountain View, CA

Locations

  • United States

Companies

  • BERG, LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Docetaxel

  • Ubidecarenone

  • Adrucil injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01957735

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved